These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 37457361)
1. FAM72 family proteins as poor prognostic markers in clear cell renal carcinoma. Gou H; Chen P; Wu W Biochem Biophys Rep; 2023 Sep; 35():101506. PubMed ID: 37457361 [TBL] [Abstract][Full Text] [Related]
2. Family with Sequence Similarity 72 (FAM72) - A prospective biomarker for poor prognosis in patients with oral squamous cell carcinoma. Liu H; Huang Y; Chen Y; Tang Z; Huang M; Ming Y; Wang M; Chen W; Huang Z; Qing L; Wang Q; Jia B Arch Oral Biol; 2023 Jul; 151():105695. PubMed ID: 37086493 [TBL] [Abstract][Full Text] [Related]
3. FAM72 serves as a biomarker of poor prognosis in human lung adenocarcinoma. Yu Y; Wang Z; Zheng Q; Li J Aging (Albany NY); 2021 Mar; 13(6):8155-8176. PubMed ID: 33686947 [TBL] [Abstract][Full Text] [Related]
4. Systematic analyses of the role of prognostic and immunological EIF3A, a reader protein, in clear cell renal cell carcinoma. Zhang Y; Hua X; Shi H; Zhang L; Xiao H; Liang C Cancer Cell Int; 2021 Dec; 21(1):680. PubMed ID: 34923969 [TBL] [Abstract][Full Text] [Related]
5. A comprehensive analysis of MYO6 as a promising biomarker for diagnosis, prognosis, and immunity in clear cell renal cell carcinoma. Meng W; Chen B; Jiang Z; Cai B; Ma L; Guan Y Transl Cancer Res; 2023 Aug; 12(8):2071-2098. PubMed ID: 37701098 [TBL] [Abstract][Full Text] [Related]
6. A comprehensive analysis of the prognostic value and immune infiltration of low expression DBT in clear cell renal cell carcinoma. Xie W; Xi P; Liu Y; Zhang Z; Sun T Front Pharmacol; 2022; 13():1002588. PubMed ID: 36299888 [No Abstract] [Full Text] [Related]
7. PTPRO predicts patient prognosis and correlates with immune infiltrates in human clear cell renal cell carcinoma. Gan J; Zhang H Transl Cancer Res; 2020 Aug; 9(8):4800-4810. PubMed ID: 35117843 [TBL] [Abstract][Full Text] [Related]
8. Low expression of SLC34A1 is associated with poor prognosis in clear cell renal cell carcinoma. Qiu J; Wang Z; Xu Y; Zhao L; Zhang P; Gao H; Wang Q; Xia Q BMC Urol; 2023 Mar; 23(1):45. PubMed ID: 36978048 [TBL] [Abstract][Full Text] [Related]
9. Wang B; Liu B; Luo Q; Sun D; Li H; Zhang J; Jin X; Cheng X; Niu J; Yuan Q; Chen Y Transl Cancer Res; 2022 Jul; 11(7):2321-2337. PubMed ID: 35966310 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of MAX dimerization protein 3 (MXD3) predicts poor prognosis in clear cell renal cell carcinoma. Zhang F; Liu L; Wu P; Li S; Wei D Transl Androl Urol; 2021 Feb; 10(2):785-796. PubMed ID: 33718080 [TBL] [Abstract][Full Text] [Related]
11. The value of EYA1/3/4 in clear cell renal cell carcinoma: a study from multiple databases. Liu T; Nie J; Zhang X; Deng X; Fu B Sci Rep; 2023 May; 13(1):7442. PubMed ID: 37156847 [TBL] [Abstract][Full Text] [Related]
12. POLD1 as a Prognostic Biomarker Correlated with Cell Proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma. Tian J; Cheng C; Gao J; Fu G; Xu Z; Chen X; Wu Y; Jin B Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047824 [TBL] [Abstract][Full Text] [Related]
13. The Downregulation of Prognosis- and Immune Infiltration-Related Gene CYFIP2 Serves as a Novel Target in ccRCC. Tong J; Meng X; Lv Q; Yuan H; Li W; Xiao W; Zhang X Int J Gen Med; 2021; 14():6587-6599. PubMed ID: 34703279 [TBL] [Abstract][Full Text] [Related]
14. Upregulation of ARNTL2 is associated with poor survival and immune infiltration in clear cell renal cell carcinoma. Wang S; Ma X; Ying Y; Sun J; Yang Z; Li J; Jin K; Wang X; Xie B; Zheng X; Liu B; Xie L Cancer Cell Int; 2021 Jul; 21(1):341. PubMed ID: 34217271 [TBL] [Abstract][Full Text] [Related]
15. Multi-Omics Analysis of the Prognosis and Biological Function for TRPV Channel Family in Clear Cell Renal Cell Carcinoma. Jiang Y; Han D; Zhao Y; Zhang C; Shi X; Gu W Front Immunol; 2022; 13():872170. PubMed ID: 35558077 [TBL] [Abstract][Full Text] [Related]
16. FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity. Dong K; Chen W; Pan X; Wang H; Sun Y; Qian C; Chen W; Wang C; Yang F; Cui X BMC Cancer; 2022 Feb; 22(1):140. PubMed ID: 35120484 [TBL] [Abstract][Full Text] [Related]
17. ADAM metallopeptidase domain 12 overexpression correlates with prognosis and immune cell infiltration in clear cell renal cell carcinoma. Gao J; Yang D; Xu H; Yang K; Ma J; Xia J; Pan X Bioengineered; 2022 Feb; 13(2):2412-2429. PubMed ID: 35094638 [TBL] [Abstract][Full Text] [Related]
18. Decreased expression of METTL14 predicts poor prognosis and construction of a prognostic signature for clear cell renal cell carcinoma. Wang Y; Cong R; Liu S; Zhu B; Wang X; Xing Q Cancer Cell Int; 2021 Jan; 21(1):46. PubMed ID: 33430867 [TBL] [Abstract][Full Text] [Related]
19. FECH Expression Correlates with the Prognosis and Tumor Immune Microenvironment in Clear Cell Renal Cell Carcinoma. Zhong G; Li Q; Luo Y; Liu Y; Liu D; Li B; Wang T J Oncol; 2022; 2022():8943643. PubMed ID: 36059798 [TBL] [Abstract][Full Text] [Related]
20. LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma. Peng Y; Greenland NY; Lang UE; Stohr BA Pathol Res Pract; 2022 Apr; 232():153831. PubMed ID: 35287088 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]